Latest Period
Q2 2026
Security Snapshot
Context Therapeutics Inc. - Common Stock, par value $0.001 per share (CNTX) Institutional Ownership
CUSIP: 21077P108
13F Institutional Holders and Ownership History from Q4 2021 to Q2 2026
Institutions Reporting
79
Shares (Excl. Options)
62,808,595
Price
$0.55
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- CNTX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 62,808,595
- Total 13F value
- $34,790,168
- Portfolio coverage rank
- 0%
- Share change
- -11,276,443
- Value change
- -$19,521,839
- Number of holders
- 79
- Shares outstanding
- 92,789,000
- SEC-reported price per share
- $0.61
- Insider filing price
- $0.61
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CNTX - Context Therapeutics Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 21077P108.
- 79 institutions reported positions in Q2 2026.
- 10 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 59 to 79 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $194,338,022 to $34,790,168.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 79 institutions filings for Q2 2026.
Security key
21077P108
Latest holder period
Q2 2026
13F holders
79
13D/G owners
10
CIK / CUSIP context first
Open Q2 2026 holders
CNTX full holder history
Context Therapeutics Inc. SEC filings
Context Therapeutics Inc. company facts
Context Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 21077P108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
10
Security
CNTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Avidity Partners Management LP | 8.7% | -12% | $21,753,357 | -$2,352,163 | 8,302,808 | -9.8% | Avidity Partners Management LP | 31 Mar 2026 |
| Deep Track Capital, LP | 8.3% | $7,419,355 | 7,419,355 | Deep Track Capital, LP | 31 Mar 2025 | |||
| Soleus Capital Master Fund, L.P. | 7.6% | +48% | $18,243,429 | +$5,729,267 | 6,963,141 | +46% | Soleus Capital Master Fund, L.P. | 31 Mar 2026 |
| BlackRock, Inc. | 6.7% | $3,401,108 | 6,169,250 | BlackRock, Inc. | 30 Jun 2026 | |||
| FRANKLIN RESOURCES INC | 4.5% | -16% | $4,003,380 | 4,003,380 | 0% | Franklin Resources, Inc. | 31 Mar 2025 | |
| Octagon Capital Advisors LP | 3.3% | -40% | $1,952,000 | -$1,408,000 | 3,050,000 | -42% | Octagon Capital Advisors LP | 30 Jun 2026 |
| Blue Owl Capital Holdings LP | 3.2% | -39% | $1,877,770 | -$1,379,200 | 2,934,015 | -42% | Blue Owl Capital Holdings LP | 30 Jun 2026 |
| GREAT POINT PARTNERS LLC | 2.4% | -53% | $5,864,860 | -$6,406,463 | 2,238,496 | -52% | Great Point Partners, LLC | 31 Mar 2026 |
| Lehr Martin A. | 2.1% | $1,595,742 | 1,595,742 | Martin Lehr | 31 Dec 2024 | |||
| MPM BioImpact LLC | 1.4% | -85% | $831,389 | -$6,003,421 | 1,299,046 | -88% | MPM BioImpact LLC | 30 Jun 2026 |
As of 30 Jun 2026, 79 institutional investors reported holding 62,808,595 shares of Context Therapeutics Inc. - Common Stock, par value $0.001 per share (CNTX). This represents 68% of the company’s total 92,789,000 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
65%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Nextech Invest Ltd. | 8% | 7,419,355 | 0% | 0.2% | $4,109,581 |
| Deep Track Capital, LP | 8% | 7,419,355 | 0% | 0.06% | $4,109,581 |
| Soleus Capital Management, L.P. | 7.6% | 7,063,141 | +1.4% | 0.13% | $3,912,274 |
| BlackRock, Inc. | 6.6% | 6,169,250 | +629% | 0% | $3,417,148 |
| Avidity Partners Management LP | 5.4% | 4,998,267 | 0% | 0.44% | $2,768,540 |
| FRANKLIN RESOURCES INC | 4.1% | 3,803,338 | 0% | 0% | $2,106,669 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 3,432,052 | +0% | 0% | $1,901,357 |
| Octagon Capital Advisors LP | 3.3% | 3,050,000 | -42% | 0.16% | $1,689,395 |
| Blue Owl Capital Holdings LP | 3.2% | 2,934,015 | -42% | 0.25% | $1,625,151 |
| TCG Crossover Management, LLC | 2.9% | 2,682,696 | 0% | 0.04% | $1,485,945 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 1,830,309 | +203% | 0% | $1,013,995 |
| STATE STREET CORP | 1.5% | 1,413,428 | +505% | 0% | $782,898 |
| MPM BIOIMPACT LLC | 1.4% | 1,299,046 | -88% | 0.04% | $719,542 |
| RENAISSANCE TECHNOLOGIES LLC | 1.1% | 1,041,399 | +469% | 0% | $576,831 |
| ACADIAN ASSET MANAGEMENT LLC | 1.1% | 1,010,904 | 0% | $559,000 | |
| ADAR1 Capital Management, LLC | 0.81% | 750,969 | +114% | 0.02% | $415,962 |
| JANE STREET GROUP, LLC | 0.7% | 645,209 | +48% | 0% | $357,382 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.69% | 638,878 | 0% | $353,938 | |
| NORTHERN TRUST CORP | 0.66% | 615,576 | +496% | 0% | $340,967 |
| VANGUARD FIDUCIARY TRUST CO | 0.47% | 433,888 | +27% | 0% | $240,374 |
| MARSHALL WACE, LLP | 0.41% | 384,528 | -87% | 0% | $211,490 |
| XTX Topco Ltd | 0.32% | 294,301 | 0% | $163,013 | |
| Qube Research & Technologies Ltd | 0.28% | 257,068 | +2155% | 0% | $142,390 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.25% | 227,850 | 0% | $126,206 | |
| Pathstone Holdings, LLC | 0.23% | 214,875 | +95% | 0% | $119,019 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
19
Latest
Q2 2026
Rows shown
1-19 of 19
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 62,808,595 | $34,790,168 | -$19,521,839 | $0.55 | 79 |
| 2026 Q1 | 74,175,436 | $194,338,022 | +$28,627,264 | $2.62 | 59 |
| 2025 Q4 | 65,197,080 | $95,840,638 | -$5,288,639 | $1.47 | 42 |
| 2025 Q3 | 68,966,266 | $66,815,968 | +$689,909 | $0.97 | 37 |
| 2025 Q2 | 68,619,580 | $44,959,003 | -$1,721,044 | $0.66 | 39 |
| 2025 Q1 | 71,405,968 | $43,712,940 | -$1,099,517 | $0.61 | 42 |
| 2024 Q4 | 72,797,034 | $76,436,064 | +$15,827,475 | $1.05 | 52 |
| 2024 Q3 | 56,682,696 | $111,154,599 | -$854,175 | $1.96 | 42 |
| 2024 Q2 | 57,034,586 | $114,325,460 | +$107,182,399 | $2.00 | 34 |
| 2024 Q1 | 3,935,132 | $5,430,813 | +$524,452 | $1.38 | 25 |
| 2023 Q4 | 3,558,639 | $4,020,714 | +$1,102,318 | $1.13 | 24 |
| 2023 Q3 | 2,578,656 | $3,893,359 | +$507,040 | $1.51 | 23 |
| 2023 Q2 | 2,239,166 | $3,582,021 | +$1,631,639 | $1.60 | 22 |
| 2023 Q1 | 1,276,355 | $717,889 | -$1,585,759 | $0.56 | 20 |
| 2022 Q4 | 3,883,345 | $2,545,096 | -$383,818 | $0.65 | 23 |
| 2022 Q3 | 4,130,839 | $4,587,000 | +$1,461,710 | $1.11 | 21 |
| 2022 Q2 | 2,747,803 | $5,761,000 | -$388,653 | $2.12 | 17 |
| 2022 Q1 | 2,904,420 | $6,302,000 | -$2,229,327 | $2.17 | 12 |
| 2021 Q4 | 3,549,370 | $9,441,000 | +$8,486,000 | $2.66 | 16 |